TIGIT is a member of the immunoglobulin superfamily and was first identified in 2009.425 Highly expressed on human and murine tumor-infiltrating T cells,426 dual PD-1/PD-L1 and TIGIT blockade is a promising combination immunotherapy for cancer. Here, PDCD1 is linked to cancer.